Market›Health Care›Health Care Equipment & Supplies›Health Care Equipment
VIVOS INC

RDGL

$0.07Apr 26, 2021 – Apr 24, 2026
Health CareHealth Care Equipment & SuppliesHealth Care Equipment$39M
MVM
-$1.4M
TD Variance
-1.071

Every news event mapped to its market reaction — 34 events, 61 months of data. No predictions, just what happened.

PositiveNegativeNo data· Dot size = magnitude · Scroll to zoom · Drag to pan
Hover to inspect

Want the full written briefing?

The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.

Subscribe on Substack →

News Events

DateReturnCategorySourceHeadline
2024-07-29-37.4%executiveInvesting.comVivos Inc CEO buys $4675 worth of company stock - Investing.com
2025-08-14-35.6%earningsStock TitanFDA Denies Vivos' Radiogel Trial at Mayo Clinic, Company Plans Swift Resubmission - Stock Titan
2025-04-25+19.0%newsStock TitanRDGL Stock Price, News & Analysis - Stock Titan
2024-07-01-17.3%legalSEC EDGARRDGL 8-K: 8.01 and (SEC Filing)
2024-05-03-16.2%newsThe Globe and MailBarchart’s Hot Penny Stocks Screener Identifies Opportunity in Vivos (RDGL) - The Globe and Mail
2023-10-11-13.0%legalSEC EDGARRDGL 8-K: 8.01 and (SEC Filing)
2025-04-15+8.9%newsStock TitanBreakthrough Cancer Treatment Proves Safe in Clinical Trial, Targets $5.89B Market - Stock Titan
2026-01-28-8.7%newsGlobeNewswireVivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL™ Trademark Approvals
2022-01-27-7.6%legalSEC EDGARRDGL 8-K: 8.01 and (SEC Filing)
2026-02-10+7.4%earningsGlobeNewswireVivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™
2026-02-10+7.4%legalStock TitanCancer-targeting gel edges toward U.S. human trials after FDA work - Stock Titan
2026-04-15-7.1%newsGlobeNewswireVivos Therapeutics Reports Full Year 2025 Financial Results
2026-04-15-7.1%newsGlobeNewswireVivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call
2025-02-10+6.2%legalSEC EDGARRDGL 8-K: 8.01 and (SEC Filing)
2025-02-10+6.2%legalSEC EDGARRDGL 8-K: 3.02 and 8.01 (SEC Filing)
2024-03-25+5.4%legalSEC EDGARRDGL 8-K: 1.01, 5.02 (SEC Filing)
2026-02-17-5.1%newsGlobeNewswireVivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites
2026-02-17-5.1%newsStock TitanInside Vivos' push for U.S. and India plants to grow gel therapies - Stock Titan
2026-02-17-5.1%newssimplywall.stGaia Leads The Charge With 2 Other Promising Penny Stocks - simplywall.st
2021-05-07+4.3%legalSEC EDGARRDGL 8-K: 1.01, 5.02 (SEC Filing)
2026-03-26+3.7%newsGlobeNewswireVivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market
2026-02-03+3.6%newsGlobeNewswireVivos Inc Updates Human Therapy Progress in India
2026-01-02-3.5%executiveInvesting.comVivos CEO Korenko buys $12920 in RDGL stock - Investing.com
2023-12-27-3.3%legalSEC EDGARRDGL 8-K: 3.02, 8.01 (SEC Filing)
2025-09-24-3.3%legalSEC EDGARRDGL 8-K: 1.01, 5.02 (SEC Filing)
2026-04-07-3.2%newsGlobeNewswireVivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners
2026-03-17+2.7%newsGlobeNewswireRecent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy
2022-07-11+2.5%legalSEC EDGARRDGL 8-K: 3.02, 8.01 (SEC Filing)
2025-12-22-2.1%newsStock TitanCancer-fighting pet therapy soars 1,200% as more vets join in 2025 - Stock Titan
2023-05-02-1.8%legalSEC EDGARRDGL 8-K: 3.02 and 8.01 (SEC Filing)
2025-03-24-1.2%earningsqz.comVivos Inc (RDGL) reports earnings - qz.com
2025-09-18-1.1%legalSEC EDGARRDGL 8-K: 8.01 (SEC Filing)
2026-02-05+0.6%legalGlobeNewswireVivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth’s Groundbreaking FDA-Cleared Allergy and Sleep Technologies
2025-09-22+0.3%legalSEC EDGARRDGL 8-K: 1.01, 5.02 (SEC Filing)
tickerdossier.comtickerdossier.substack.com